Potential New Treatments for Chronic Kidney Diseases: A Concise Review

References

1. American Diabetes Association Diabetes Complications: Diabetes, High Blood Pressure, and Chronic Kidney Disease (CKD). Available from: https://diabetes.org/about-diabetes/complications/chronic-kidney-disease/diabetes-high-blood-pressure-chronic-kidney-disease Accessed on August 15, 2024.
2. Thomas R. Kanso A. Sedor J.R. Chronic kidney disease and its complications. Prim. Care 2008 35 2 329 344, vii 10.1016/j.pop.2008.01.008 18486718
   [Google Scholar]
3. Vaidya S.R. Aeddula N.R. Chronic Kidney Disease. StatPearls. Treasure Island, FL StatPearls Publishing 2024
   [Google Scholar]
4. Centers for Disease Control and Prevention Chronic Kidney Disease in the United States, 2021. Centers for Disease Control and Prevention, US Department of Health and Human. 2021 Available from: https://www.cdc.gov/kidneydisease/pdf/Chronic-Kidney-Disease-in-the-US-2021-h.pdf Accessed on August 26, 2023.
5. United States Renal Data System USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services. 2022 Available from: https://usrds-adr.niddk.nih.gov/2022 Accessed August 26, 2023.
6. National institute of diabetes and digestive and kidney diseases. Available from: https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease Accessed on December 25, 2023.
7. Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels. (CONCORD). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04507061 Accessed on August 26, 2023.
8. A study of cotadutide in participants who have chronic kidney disease with type 2 diabetes mellitus. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04515849?cond=Cotadutide&draw=2&rank=2 Accessed on August 26, 2023.
9. Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysis (CONVERT). Available from: https://classic.clinicaltrials.gov/ct2/show/results/NCT04523220?cond=Osocimab&draw=2&rank=1 Accessed on August 26, 2023.
10. Patel R. Fu Y. Khang S. Benardeau A.M. Thomson S.C. Vallon V. Responses in blood pressure and kidney function to soluble guanylyl cyclase stimulation or activation in normal and diabetic rats. Nephron J. 2023 147 5 281 300 10.1159/000526934 36265461
    [Google Scholar]
11. Bénardeau A. Kahnert A. Schomber T. Meyer J. Pavkovic M. Kretschmer A. Lawrenz B. Hartmann E. Mathar I. Hueser J. Kraehling J.R. Eitner F. Hahn M.G. Stasch J.P. Sandner P. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch. Pharmacol. 2021 394 12 2363 2379 10.1007/s00210‑021‑02149‑4 34550407
    [Google Scholar]
12. Stehle D. Xu M.Z. Schomber T. Hahn M.G. Schweda F. Feil S. Kraehling J.R. Eitner F. Patzak A. Sandner P. Feil R. Bénardeau A. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. Br. J. Pharmacol. 2022 179 11 2476 2489 10.1111/bph.15586 34096053
    [Google Scholar]
13. Hahn M.G. Lampe T. El Sheikh S. Griebenow N. Woltering E. Schlemmer K.H. Dietz L. Gerisch M. Wunder F. Becker-Pelster E.M. Mondritzki T. Tinel H. Knorr A. Kern A. Lang D. Hueser J. Schomber T. Benardeau A. Eitner F. Truebel H. Mittendorf J. Kumar V. van den Akker F. Schaefer M. Geiss V. Sandner P. Stasch J.P. Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042). J. Med. Chem. 2021 64 9 5323 5344 10.1021/acs.jmedchem.0c02154 33872507
    [Google Scholar]
14. Al-Horani R.A. Chedid M. Tirzepatide: A new generation therapeutic for diabetes type 2. Endocr. Metab. Immune Disord. Drug Targets 2023 23 8 1046 1050 10.2174/1871530322666221004151212 36200219
    [Google Scholar]
15. Li Y. Zhou Q. Dai A. Zhao F. Chang R. Ying T. Wu B. Yang D. Wang M.W. Cong Z. Structural analysis of the dual agonism at GLP-1R and GCGR. Proc. Natl. Acad. Sci. USA 2023 120 33 e2303696120 10.1073/pnas.2303696120 37549266
    [Google Scholar]
16. Jiang N. Jing L. Li Q. Su S. Yang Q. Zhou F. Chen X. Han J. Tang C. Tang W. Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. Eur. J. Med. Chem. 2021 212 113118 10.1016/j.ejmech.2020.113118 33422984
    [Google Scholar]
17. Ambery P.D. Klammt S. Posch M.G. Petrone M. Pu W. Rondinone C. Jermutus L. Hirshberg B. MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study. Br. J. Clin. Pharmacol. 2018 84 10 2325 2335 10.1111/bcp.13688 29926478
    [Google Scholar]
18. Schaefer M. Buchmueller A. Dittmer F. Straßburger J. Wilmen A. Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor xi. J. Mol. Biol. 2019 431 24 4817 4833 10.1016/j.jmb.2019.09.008 31655039
    [Google Scholar]
19. Weitz J.I. Bauersachs R. Becker B. Berkowitz S.D. Freitas M.C.S. Lassen M.R. Metzig C. Raskob G.E. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty. JAMA 2020 323 2 130 139 10.1001/jama.2019.20687 31935028
    [Google Scholar]
20. Beavers C.J. Wayne N.B. Osocimab: A novel agent in preventing venous thromboembolism. J. Cardiovasc. Pharmacol. 2020 76 6 645 649 10.1097/FJC.0000000000000921 33105325
    [Google Scholar]
21. Jones A. Al-Horani R.A. Venous thromboembolism prophylaxis in major orthopedic surgeries and factor XIa inhibitors. Med. Sci. 2023 11 3 49 10.3390/medsci11030049 37606428
    [Google Scholar]
22. Minnaard-Huiban M. Emmen J.M.A. Roumen L. Beugels I.P.E. Cohuet G.M.S. van Essen H. Ruijters E. Pieterse K. Hilbers P.A.J. Ottenheijm H.C.J. Plate R. de Gooyer M.E. Smits J.F.M. Hermans J.J.R. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: Discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology 2008 149 1 28 31 10.1210/en.2007‑0584 17884944
    [Google Scholar]
23. Kohan D.E. Lambers Heerspink H.J. Coll B. Andress D. Brennan J.J. Kitzman D.W. Correa-Rotter R. Makino H. Perkovic V. Hou F.F. Remuzzi G. Tobe S.W. Toto R. Parving H.H. de Zeeuw D. Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 2015 10 9 1568 1574 10.2215/CJN.00570115 26153128
    [Google Scholar]
24. Koomen J.V. Stevens J. Bakris G. Correa-Rotter R. Hou F.F. Kitzman D.W. Kohan D.E. Makino H. McMurray J.J.V. Parving H.H. Perkovic V. Tobe S.W. de Zeeuw D. Heerspink H.J.L. Individual atrasentan exposure is associated with long‐term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease. Clin. Pharmacol. Ther. 2021 109 6 1631 1638 10.1002/cpt.2143 33338269
    [Google Scholar]
25. Heerspink H.J.L. Parving H.H. Andress D.L. Bakris G. Correa-Rotter R. Hou F.F. Kitzman D.W. Kohan D. Makino H. McMurray J.J.V. Melnick J.Z. Miller M.G. Pergola P.E. Perkovic V. Tobe S. Yi T. Wigderson M. de Zeeuw D. Elbert A. Vallejos A. Alvarisqueta A. Maffei L. Juncos L. de Arteaga J. Greloni G. Farias E. Zucchini A. Vogel D. Cusumano A. Santos J. Fraenkel M. Gallagher M. Davis T. Acharya S. Cooke D. Suranyi M. Roger S. Toussaint N. Pollock C. Chan D. Stranks S. MacIsaac R. Endre Z. Schmidt A. Prager R. Mayer G. Warling X. Jadoul M. Hougardy J. Vercammen C. Van Vlem B. Gillard P. Costa e Forti A. Borges J.L. Santos Canani L. Eliaschewitz F. Leite S. Fraige Filho F. Paschoalin R. Moura Neto J.A. Deboni L. de Lourdes Noronha I. Cercato C. Prompt C.A. Zanella M. Rassi N. D’Avila D. Milagres R. Felicio J. Pecoits Filho R. Riella M.C. Salles J. Keitel E. Draibe S. Amodeo C. Youmbissi J. Roy L. Cournoyer S. Jolly S. Pichette V. Nesrallah G. Bajaj H.S. Khandwala H. Aronson R. Goluch R. Tam P. Rabbat C. Tobe S. Bailey G. Chow S. Castillo A. Danin Vargas A. Gonzalez F. Munoz R. Gutierrez V. Godoy G. Zhao H. Liu Z. Zhao M. Guo X. Su B. Fu S. Xu Y. Yang J. Shi B. Xiao G. Shi W. Hao C. Xing C. Hou F. Luo Q. Li Y. Ji L. Zuo L. Wang S. Ni Z. Ding G. Chen N. Zhao J. Jia W. Yu S. Weng J. Xu G. Fu P. Sun S. Liu B. Ding X. Rychlik I. Oplustilova A. Bartaskova D. Honova V. Chmelickova H. Petr M. Bucek P. Tesar V. Zahumensky E. Povlsen J. Egstrup K. Oczachowska-Kulik A. Rossing P. Lahtela J. Strand J. Kantola I. Petit C. Combe C. Zaoui P. Esnault V. Urena Torres P. Halimi J-M. Dussol B. Bieler T. Budde K. Dellanna F. Segiet T. Kosch C. Schmidt-Guertler H. Schenkenberger I. Vielhauer V. Pistrosch F. Alscher M. Hasslacher C. Hugo C. Muehlfeld A. Wanner C. Passadakis P. Apostolou T. Tentolouris N. Stefanidis I. Mavromatidis K. Liakopoulos V. Goumenos D. Siamopoulos K. Yeung V. Ozaki R. Fung S. Tan K. Tang S. Lui S.L. Cheung S.F. Sreenan S. Eustace J. O’Shea D. Lavin P. Stack A. Yagil Y. Wainstein J. Knobler H. Cohen J. Kenis I. Daoud D. Bar-Dayan Y. Frajewicki V. Adawi F. Gesualdo L. Santoro D. Marino F. Galfre A. Brunati C. Ruggenenti P. Rombola G. Pugliese G. Ravera M. Malberti F. Pontoriero G. Rampino T. De Cosmo S. Esposito C. Nappi F. Abaterusso C. Conte G. Panichi V. Lauro D. Capasso G. Russo D. Anzai J. Naka M. Ato K. Tsujimoto T. Nimura T. Nakashima E. Takeda T. Fujii S. Kobayashi K. Iwaoka H. Nagayama K. Harada H. Maeda H. Kishimoto R. Iitsuka T. Itabashi N. Furuya R. Maeda Y. Yamada D. Sasaki N. Sasaki H. Ueda S. Kashihara N. Watanabe S. Nakamura T. Kanai H. Makita Y. Ono K. Iehara N. Goto D. Kosuge K. Tsuchida K. Sato T. Sekikawa T. Okamoto H. Tanaka T. Ikeda N. Tadika T. Mukasa K. Osonoi T. Hirano F. Nishimura M. Yambe Y. Tanaka Y. Ujihara M. Sakai T. Imura M. Umayahara Y. Makino S. Nakazawa J. Yamaguchi Y. Kashine S. Miyaoka H. Suzuki K. Inoue T. Nagai S. Sato N. Yamamoto M. Taya N. Fujita A. Matsutani A. Shibagaki Y. Sato Y. Yamauchi A. Tsutsui M. Ishiko T. Kaneko S. Azuma N. Matsuda H. Hashiguchi Y. Onishi Y. Tokui M. Matsuhisa M. Kiyosue A. Shinoda J. Ishikawa K. Ahmad G. Vijayasingham S. Aziz N.A. Hussein Z. Fung Y.K. Hassan W.H.H.W. Wong H.S. Goh B.L. Ali N.M. Merican N.S.Y.A. Vaithilingam I. Nik Ahmad N.N.F. Adam N. Sukor N. Vengadasalam V.P.P. Abdul Kadir K. Mohamed M. Renoirte Lopez K. Leguizamo-Dimas A. Chew Wong A. Chevaile-Ramos J. Gonzalez Gonzalez J. Rico Hernandez R. Nino-Cruz J. Sauque Reyna L. Gonzalez-Galvez G. Madero Rovalo M. Bochicchio-Ricardelli T. Aldrete J. Carranza-Madrigal J. Vogt L. Smak Gregoor P. Barendregt J.N.M. Luik P. Gansevoort R. Laverman G. Pilmore H. Lunt H. Baker J. Miller S. Rabindranath K. Zapata-Rincon L. Vargas-Gonzales R. Calderon Ticona J. Dextre Espinoza A. Burga Nunez J. Zea-Nunez C.A. Herrada Orue B. Medina-Santander B. Delgado-Butron C. Farfan-Aspilcueta J. Mazur S. Necki M. Wruk M. Klodawska K. Popenda G. Skokowska E. Arciszewska M. Wiecek A. Ciechanowski K. Nowicki M. Birne R. Cabrita A. Ramos A. Antunes Ferreira M.A. Matta Fontanet E. Alcantara-Gonzalez A.A. Comulada-Rivera A. Galindo Ramos E. Cangiano J. Quesada-Suarez L. Calderon Ortiz R. Vazquez-Tanus J. Burgos-Calderon R. Rosado C. Hancu N. Pintilei E. Mistodie C. Bako G. Ionutiu L. Petrica L. Timar R. Tuta L. Duma L. Tutescu A. Ivanova S. Essaian A. Zrazhevskiy K. Tomilina N. Smolyarchuk E. Kuzin A. Lantseva O. Karpova I. Shamkhalova M. Liberanskaya N. Yavdosyuk A. Shvarts Y. Bardymova T. Blagoveshchenskaya O. Solovev O. Rechkova E. Pikalova N. Pavlova M. Kolmakova E. Sayfutdinov R. Villevalde S. Koziolova N. Martynenko V. Marasaev V. Maksudova A. Sigitova O. Mordovin V. Klimontov V. Samoylova Y. Karonova T. Yeoh L.Y. Teo B.W. Foo M.W.Y. Liew A. Tkac I. Oroszova A. Fekete J. Rosenberger J. Obetkova I. Fulopova A. Kolesarova E. Raslova K. Smolko P. Oksa A. Distiller L. Trokis J. Adams L. Makan H. Ramlachan P. Mitha E. Coetzee K. Punt Z. Bhorat Q. Naiker P. Ellis G. Van Zyl L. Lee K.W. Kim M.S. Yoo S-J. Yoon K.H. Cho Y-W. Park T-S. Kim S.Y. Choi M-G. Oh T.K. Lee K-W. Shon H.S. Suh S.H. Kim B-J. Doo-Man K. Yi J.H. Lee S.A. Cho H.C. Kim S-G. Cha D-R. Seo J.A. Choi K.M. Woo J-T. Ahn K.J. Lee J.H. Kim I-J. Lee M-K. Jang H.C. Park K-S. Kim B.S. Mok J.O. Shin M. Yoon S.A. Nam-Goong I-S. Chung C.H. Yu T.Y. Lee H.W. Soto Gonzalez A. Almirall J. Egido J. Calero Gonzalez F. Fernandez Fresnedo G. Valera Cortes I. Praga Terente M. Garcia Mendez I. Navarro Gonzalez J. Herrero Calvo J. Cigarran Guldris S. Prieto Velasco M. Minguela Pesquera J.I. Galan A. Pascual J. Marques Vidas M. Martins Munoz J. Rodriguez-Perez J. Castro-Alonso C. Bonet Sol J. Seron D. Fernandez Giraldez E. Arrieta Lezama J. Montero N. Hernandez-Jaras J. Santamaria Olmo R. Molas Coten J.R. Hellberg O. Fellstrom B. Bock A. Pei D. Lin C-L. Tien K-J. Chen C-C. Huang C-N. Jiang J-Y. Wu D-A. Chu C-H. Tseng S-T. Chen J-F. Bau C-T. Sheu W. Wu M-S. Sari R. Sezer S. Yildiz A. Satman I. Kalender B. Mankovskyy B. Fushtey I. Stanislavchuk M. Kolenyk M. Dudar I. Zolotaikina V. Abrahamovych O. Kostynenko T. Petrosyan O. Kuskalo P. Galushchak O. Legun O. Topchii I. Martynyuk L. Stryzhak V. Panina S. Tkach S. Korpachev V. Maxwell P. Gnudi L. Kon S.P. Tindall H. Kalra P. Mark P. Patel D. El-Shahawy M. Bai L. Nica R. Lien Y-H. Menefee J. Busch R. Miller A. Ahmed A. Arif A. Lee J. Desai S. Bansal S. Bentsianov M. Belledonne M. Jere C. Gaona R. Greenwood G. Brusco O. Boiskin M. Belo D. Minasian R. Atray N. Lawrence M. Taliercio J. Pergola P. Scott D. Alvarez G. Marder B. Powell T. Bakdash W. Stoica G. McFadden C. Rendell M. Wise J. Jones A. Jardula M. Madu I-J. Varghese F. Tulloch B. Ahmed Z. Hames M. Nazeer I. Shahid N. John R. Montero M. Fitz-Patrick D. Phillips L. Guasch A. Christofides E. Gundroo A. Amin M. Bowman-Stroud C. Link M. Mulloy L. Nammour M. Lalwani T. Hanson L. Whaley-Connell A. Herman L. Chatha R. Osama S. Liss K. Kayali Z. Bhargava A. Israel E. Peguero-Rivera A. Fang M. Slover J. Barengolts E. Flores J. Muoneke R. Savin V. Awua-Larbi S. Levine A. Newman G. Golestaneh L. Bohm G. Reisin E. Cruz L. Weiss R. Zieve F. Horwitz E. Chuang P. Mersey J. Manley J. Graf R. Bedros F. Joshi S. Frias J. Assefi A. O’Shaughnessy A. Brantley R. Minga T. Tietjen D. Kantor S. Jamal A. Guadiz R. Hershon K. Bressler P. Kopyt N. Cathcart H. Bloom S. Reichel R. Nakhle S. Dulude E. Tarkan J. Baker P. Zeig S. Moya Hechevarria J. Ropero-Cartier A. De la Calle G. Doshi A. Saba F. Sligh T. Shaw S. Kumar J. Szerlip H. Bayliss G. Perlman A. Sakhrani L. Gouge S. Argoud G. Acosta I. Elder J. Joshi S. Sensenbrenner J. Vicks S. Mangoo-Karim R. Galphin C. Leon-Forero C. Gilbert J. Brown E. Ijaz A. Butt S. Markell M. Arauz-Pacheco C. Sloan L. Alvarado O. Jabbour S. Simon E. Rastogi A. James S. Bakris G. Hall K. Melish J. Dixon B. Adolphe A. Kovesdy C. Beddhu S. Solomon R. Fernando R. Levin E. Thakar C. Robey B. Goldfarb D. Fried L. Maddukuri G. Thomson S. Annand A. Kronfli S. Kalirao P. Schmidt R. Dahl N. Blumenthal S. Weinstein D. Ostergaard O. Weinstein T. Ono Y. Yalcin M. Karim S. SONAR Committees and Investigators Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019 393 10184 1937 1947 10.1016/S0140‑6736(19)30772‑X 30995972
    [Google Scholar]
26. Ortiz A. Fernandez-Fernandez B. Atrasentan: the difficult task of integrating endothelin a receptor antagonists into current treatment paradigm for diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2021 16 12 1775 1778 10.2215/CJN.13601021 34853063
    [Google Scholar]
27. Trachtman H. Nelson P. Adler S. Campbell K.N. Chaudhuri A. Derebail V.K. Gambaro G. Gesualdo L. Gipson D.S. Hogan J. Lieberman K. Marder B. Meyers K.E. Mustafa E. Radhakrishnan J. Srivastava T. Stepanians M. Tesar V. Zhdanova O. Komers R. DUET Study Group DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 2018 29 11 2745 2754 10.1681/ASN.2018010091 30361325
    [Google Scholar]
28. Dhaun N. MacIntyre I.M. Kerr D. Melville V. Johnston N.R. Haughie S. Goddard J. Webb D.J. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011 57 4 772 779 10.1161/HYPERTENSIONAHA.110.167486 21357275
    [Google Scholar]
29. Ohnishi A. Orita Y. Okahara R. Fujihara H. Inoue T. Yamamura Y. Yabuuchi Y. Tanaka T. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 1993 92 6 2653 2659 10.1172/JCI116881 8254021
    [Google Scholar]
30. Nelson J.B. Endothelin receptor antagonists. World J. Urol. 2005 23 1 19 27 10.1007/s00345‑004‑0478‑9 15654644
    [Google Scholar]
31. Enevoldsen F.C. Sahana J. Wehland M. Grimm D. Infanger M. Krüger M. Endothelin receptor antagonists: Status quo and future perspectives for targeted therapy. J. Clin. Med. 2020 9 3 824 10.3390/jcm9030824 32197449
    [Google Scholar]
32. Schlaich M.P. Bellet M. Weber M.A. Danaietash P. Bakris G.L. Flack J.M. Dreier R.F. Sassi-Sayadi M. Haskell L.P. Narkiewicz K. Wang J.G. Reid C. Schlaich M. Katz I. Ajani A. Biswas S. Esler M. Elder G. Roger S. Colquhoun D. Mooney J. De Backer T. Persu A. Chaumont M. Krzesinski J-M. Vanassche T. Girard G. Pliamm L. Schiffrin E. Merali F. Dresser G. Vallee M. Jolly S. Chow S. Wang J. Mu J. Yu J. Yuan H. Feng Y. Zhang X. Xie J. Lin L. Soucek M. Widimsky J. Cifkova R. Vaclavik J. Ullrych M. Lukac M. Rychlik I. Guldager Lauridsen T. Kantola I. Taurio J. Ukkola O. Ormezzano O. Gosse P. Azizi M. Courand P-Y. Delsart P. Tartiere J.M. Mahfoud F. Schmieder R. Stegbauer J. Lurz P. Koziolek M. Ott C. Toursarkissian N. Tsioufis K. Kyfnidis K. Manolis A. Patsilinakos S. Zebekakis P. Karavidas A. Denes P. Bezzegh K. Zsom M. Kovacs L. Sharabi Y. Elias M. Sukholutsky I. Yosefy C. Kenis I. Atar S. Volpe M. Maria Lorenza M. Taddei S. Grassi G. Veglio F. Son J.W. Kim J-Y. Park J-I. Lee C.H. Lee H-Y. Raugaliene R. Marcinkeviciene J.E. Kavaliauskiene R. Deinum J. Kroon A. van den Born B-J. Januszewicz A. Tykarski A. Walczewska J. Gaciong Z. Wiecek A. Chrostowska M. Kleinrok A. Krekora J. Kania G. Podrazka-Szczepaniak A. Golawski C. Podziewski M. Kaczmarek B. Skoczylas G. Wilkolaski A. Wozniak I. Janik-Palazzolo M. Rewerska B. Konradi A. Shvarts Y. Pecherina T. Nikolaev K. Liudmila G. Orlikova O. Mordovin V. Petrochenkova N. Kamalov G. Kosmacheva E. Nikolaev K. Tyrenko V. Gorbunov V. Obrezan A. Supryadkina T. Ler I. Kotenko O. Kuzin A. Martínez García F. Redon J. Oliveras A. Beltran Romero L. Shatylo V. Rudenko L. Bazylevych A. Rudyk Y. Karpenko O. Stanislavchuk M. Tseluyko V. Kushnir M. Asanov E. Sirenko Y. Yagensky A. Collier D. Gupta P. Webb D. MacLeod M. McLay J. Peace A. Arora S. Buchanan P. Harris R. Degarmo R. Guillen M. Karns A. Neutel J. Paliwal Y. Pettis K. Toth P.D. Wayne J.M. Butcher M.B. Diller P.M. Oparil S. Calhoun D. Brautigam D. Flack J. Goldman J.M. Rashidi A. Aslam N. Haley W. Andrawis N. Lang B. Miller R. Powell J. Dewhurst R. Pritchard J. Khanna D. Tang D. Gabra N. Park J. Jones C. Scott C. Luna B. Mussaji M. Bhagwat R. Bauer M. McGinty J. Nambiar R. Sangrigoli R. Davis W.R. Eaves W. McGrew F. Awad A. Bolster E. Scott D. Kalirao P. Dabel P. Calhoun W. Gouge S. Warren M. Lawrence M.K. Jamal A. El-Shahawy M. Mercado C. Kumar J. Velasquez-Mieyer P. Busch R. Lewis T. Rich L. PRECISION investigators Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022 400 10367 1927 1937 10.1016/S0140‑6736(22)02034‑7 36356632
    [Google Scholar]
33. Wenzel R.R. Littke T. Kuranoff S. Jürgens C. Bruck H. Ritz E. Philipp T. Mitchell A. SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 2009 20 3 655 664 10.1681/ASN.2008050482 19144760
    [Google Scholar]
34. Wang Y. Chen S. Du J. Bosentan for treatment of pediatric idiopathic pulmonary arterial hypertension: State-of-the-art. Front Pediatr. 2019 7 302 10.3389/fped.2019.00302 31396496
    [Google Scholar]
35. Liang F. Glascock C.B. Schafer D.L. Sandoval J. Cable L. Melvin L. Jr Hartman J.C. Pitts K.R. Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteriesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research. Can. J. Physiol. Pharmacol. 2010 88 8 840 849 10.1139/Y10‑061 20725142
    [Google Scholar]
36. Davenport A.P. Hyndman K.A. Dhaun N. Southan C. Kohan D.E. Pollock J.S. Pollock D.M. Webb D.J. Maguire J.J. Endothelin. Pharmacol. Rev. 2016 68 2 357 418 10.1124/pr.115.011833 26956245
    [Google Scholar]
37. Scott L.J. Sitaxentan. Drugs 2007 67 5 761 770 10.2165/00003495‑200767050‑00007 17385944
    [Google Scholar]
38. Komers R. Diva U. Inrig J.K. Loewen A. Trachtman H. Rote W.E. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int. Rep. 2020 5 4 494 502 10.1016/j.ekir.2019.12.017 32274453
    [Google Scholar]
39. Martínez-Díaz I. Martos N. Llorens-Cebrià C. Álvarez F.J. Bedard P.W. Vergara A. Jacobs-Cachá C. Soler M.J. Endothelin receptor antagonists in kidney disease. Int. J. Mol. Sci. 2023 24 4 3427 10.3390/ijms24043427 36834836
    [Google Scholar]
40. Stern E.P. Host L.V. Wanjiku I. Escott K.J. Gilmour P.S. Ochiel R. Unwin R. Burns A. Ong V.H. Cadiou H. O’Keeffe A.G. Denton C.P. Zibotentan in systemic sclerosis-associated chronic kidney disease: A phase II randomised placebo-controlled trial. Arthritis Res. Ther. 2022 24 1 130 10.1186/s13075‑022‑02818‑6 35650639
    [Google Scholar]
41. Heerspink H.J.L. Greasley P.J. Ahlström C. Althage M. Dwyer J.P. Law G. Wijkmark E. Lin M. Mercier A.K. Sunnåker M. Turton M. Wheeler D.C. Ambery P. Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: Study design and baseline characteristics of the ZENITH-CKD trial. Nephrol. Dial. Transplant. 2023 gfad183 37632201
    [Google Scholar]
42. Chebib F.T. Dahl N.K. CKD risk stratification. J. Am. Soc. Nephrol. 2024 35 9 1146 1148 10.1681/ASN.0000000000000455 39053619
    [Google Scholar]
43. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 105 4S S117 S314 38490803
    [Google Scholar]
44. Kalantar-Zadeh K. Joshi S. Schlueter R. Cooke J. Brown-Tortorici A. Donnelly M. Schulman S. Lau W.L. Rhee C. Streja E. Tantisattamo E. Ferrey A. Hanna R. Chen J. Malik S. Nguyen D. Crowley S. Kovesdy C. Plant-dominant low-protein diet for conservative management of chronic kidney disease. Nutrients 2020 12 7 1931 10.3390/nu12071931 32610641
    [Google Scholar]
45. Zha Y. Qian Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients 2017 9 3 208 10.3390/nu9030208 28264439
    [Google Scholar]
46. Caldarelli M. Franza L. Rio P. Gasbarrini A. Gambassi G. Cianci R. Gut–kidney–heart: A novel trilogy. Biomedicines 2023 11 11 3063 10.3390/biomedicines11113063 38002063
    [Google Scholar]